跳至主要内容
临床试验/EUCTR2013-004420-11-BE
EUCTR2013-004420-11-BE进行中(未招募)1 期

Azithromycin for acute COPD exacerbations with hospitalisation: the BACE trial - BACE

KU Leuven - UZ Leuven0 个研究点目标入组 301 人开始时间: 2014年2月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
301

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1/ Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)
  • 2/ Smoking history (= 10 pack-years)
  • 3/ Current hospitalization for potential infectious AECOPD treated with standard therapy
  • 4/ History of at least one exacerbation during the last year for which systemic steroids and/or antibiotics were taken
  • 5/ ECG at admission
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 300

排除标准

  • 1/ Mechanical or non-invasive ventilation at moment of randomisation (D1)
  • 2/ Long QT interval on ECG (QTc > 450msec for males or > 470msec for females)
  • 3/ History of life-threatening arrhythmias
  • 4/ Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before of start study
  • 5/ Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission
  • 6/ Drugs with high risk for long QT interval and torsade de pointes
  • (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides).
  • 7/ Documented uncorrected severe hypokalemia (K+ < 3.0 mmol/L) or hypomagnesemia (Mg2+ <0.5 mmol/L)
  • 8/ Chronic systemic steroids (> 4 mg methylprednisolone /day for = 2 months)
  • 9/ Actual use of macrolides for at least 2 weeks
  • 10/ Allergy to macrolides
  • 11/ Active cancer treatment
  • 12/ Life expectancy < 3 months
  • 13/ Pregnant or breast-feeding women

研究者

发起方
KU Leuven - UZ Leuven

相似试验